Form 8-K - Current report:
SEC Accession No. 0001437749-25-025441
Filing Date
2025-08-07
Accepted
2025-08-07 16:20:22
Documents
14
Period of Report
2025-08-05
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K aytu20250617_8k.htm   iXBRL 8-K 24879
6 logo01.jpg GRAPHIC 3651
  Complete submission text file 0001437749-25-025441.txt   168324

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aytu-20250805.xsd EX-101.SCH 3578
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aytu-20250805_def.xml EX-101.DEF 11806
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20250805_lab.xml EX-101.LAB 15857
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20250805_pre.xml EX-101.PRE 12021
16 EXTRACTED XBRL INSTANCE DOCUMENT aytu20250617_8k_htm.xml XML 2945
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 251194394
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)